DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR NIACIN
» See Plans and Pricing
All Clinical Trials for Niacin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000482 | Coronary Drug Project | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1965-04-01 | To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction. |
| NCT00000512 | Familial Atherosclerosis Treatment Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00000512 | Familial Atherosclerosis Treatment Study | Completed | University of Washington | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00000539 | Arterial Disease Multifactorial Intervention Trial (ADMIT) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1992-09-01 | To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Niacin
Condition Name
Clinical Trial Locations for Niacin
Trials by Country
Clinical Trial Progress for Niacin
Clinical Trial Phase
Clinical Trial Sponsors for Niacin
Sponsor Name
